What Blood Tests Detect Insulin Resistance? A Longevity Medicine Guide

There Is No Single Routine Blood Test for Insulin Resistance

Insulin resistance describes a reduced biological response to insulin. Muscle, liver and adipose tissue can each become insulin resistant, and they do not necessarily do so to the same degree or at the same time.

The most direct research method for measuring whole-body insulin sensitivity is the hyperinsulinemic-euglycemic clamp. It involves infusing insulin and glucose under tightly controlled conditions and measuring how much glucose the body requires to maintain a stable blood glucose concentration. It is valuable in research but far too cumbersome for routine clinical screening.

Clinical practice therefore relies on indirect measurements.

Some evaluate glucose regulation. Others use fasting insulin, lipids or mathematical calculations to estimate insulin sensitivity. None provides a complete answer by itself.

This is also why the phrases “normal glucose” and “normal metabolism” should not be treated as synonyms. A person can maintain normal glucose for some time by secreting more insulin, although the degree and duration of that compensation vary considerably between individuals.

Fasting Glucose

Fasting plasma glucose remains one of the standard tests for detecting abnormal glucose metabolism.

According to current American Diabetes Association criteria, fasting glucose below 100 mg/dL is considered below the prediabetes range. Fasting glucose from 100 through 125 mg/dL meets the criterion for impaired fasting glucose, while a value of 126 mg/dL or higher can meet the criterion for diabetes when appropriately confirmed.

Fasting glucose is inexpensive, widely available and clinically important. Its limitation is timing. Glucose may remain below the prediabetes threshold while insulin secretion is increasing to compensate for declining insulin sensitivity.

A normal fasting glucose therefore does not prove that insulin sensitivity is optimal.

At the same time, fasting glucose should not be dismissed simply because it may change later in the disease process. Once glucose begins to rise, that change carries meaningful information about diabetes and cardiovascular risk.

Hemoglobin A1C

Hemoglobin A1C estimates longer-term glucose exposure by measuring the percentage of hemoglobin with glucose attached to it. Because red blood cells circulate for several months, A1C provides a broader picture than a single fasting measurement.

Current diagnostic ranges define A1C below 5.7% as below the prediabetes threshold, 5.7% through 6.4% as prediabetes, and 6.5% or higher as a criterion for diabetes when appropriately confirmed.

A1C is useful, but it does not directly measure insulin sensitivity and can miss some people with abnormal glucose tolerance. The ADA notes that the 2-hour glucose value during an oral glucose tolerance test identifies more people with prediabetes and diabetes than fasting glucose or A1C alone.

A1C also has biological limitations. Anemia, altered red-blood-cell turnover, some hemoglobin variants, kidney failure, pregnancy, blood loss, transfusion and several other conditions can make the result less reliable. When A1C and measured glucose do not fit the same clinical picture, the discrepancy deserves attention rather than being averaged away.

The Oral Glucose Tolerance Test Can Reveal What Fasting Tests Miss

The 75-gram oral glucose tolerance test is less convenient than fasting glucose or A1C, but it can reveal abnormalities that are not evident from either of those tests.

After an overnight fast, a baseline glucose sample is obtained, the patient drinks a standardized glucose solution, and plasma glucose is measured again two hours later.

A 2-hour glucose value below 140 mg/dL is below the prediabetes threshold. A value from 140 through 199 mg/dL meets the criterion for impaired glucose tolerance, while 200 mg/dL or higher can meet the criterion for diabetes when confirmed appropriately.

The advantage is that the test challenges the metabolic system rather than observing it only at rest.

Some people maintain a normal fasting glucose but have difficulty handling a glucose load. In that situation, post-challenge testing can reveal impaired glucose tolerance that fasting measurements miss.

For people with substantial metabolic risk and reassuring fasting numbers, the OGTT can therefore be worth considering.

Fasting Insulin

Fasting insulin is appealing because it measures the hormone that is central to insulin resistance rather than glucose alone.

If fasting glucose remains normal while fasting insulin is progressively rising, the pattern may suggest that the pancreas is producing more insulin to maintain glucose control. In the appropriate clinical setting, that can provide useful information before overt hyperglycemia appears.

It is easy, however, to give fasting insulin more precision than the test deserves.

There is no universally accepted fasting-insulin value that defines insulin resistance, and there is no authoritative clinical guideline establishing a fasting insulin below 5 µIU/mL as the universal definition of “optimal.”

Insulin secretion varies biologically, and laboratory assays are not standardized to the degree that glucose assays are. A fasting insulin value therefore needs to be interpreted in the context of the laboratory, glucose level, body composition, triglycerides, medical history and prior results.

Serial measurements obtained under reasonably similar conditions can sometimes be more informative than attempting to assign a universal meaning to a single number.

HOMA-IR: Useful Estimate, Not a Diagnosis

HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. It combines fasting insulin and fasting glucose to estimate insulin resistance in the fasting state.

A commonly used equation when glucose is expressed in mg/dL is:

The calculation is useful because an insulin level means something different when interpreted beside glucose. An insulin of 10 µIU/mL accompanying a fasting glucose of 75 mg/dL is a different metabolic situation from the same insulin accompanying a fasting glucose of 110 mg/dL.

HOMA-IR is extensively used in research and can be clinically informative, but it does not have one universally accepted diagnostic cutoff. Reference values vary with age, sex, ethnicity, population characteristics and the insulin assay used.

Variation between insulin assays is particularly important because HOMA-IR is calculated directly from the insulin result. If laboratories measure insulin differently, HOMA-IR values can differ even when the patient's physiology has not changed.

HormoneSynergy® reviews this in more depth in HOMA-IR and Insulin Resistance: How to Interpret the Number.

Triglycerides, HDL and the TG/HDL Ratio

Insulin resistance often travels with a recognizable lipid pattern: triglycerides rise while HDL cholesterol falls.

The triglyceride-to-HDL cholesterol ratio is therefore sometimes used as a simple surrogate marker of metabolic dysfunction. It has the advantage of being calculated from a standard lipid panel without an insulin measurement.

Research supports an association between higher TG/HDL ratios and insulin resistance, but the relationship is not identical across populations. Studies have reported differences according to sex and ethnicity, and proposed thresholds vary considerably.

For that reason, there is no single TG/HDL ratio that can diagnose insulin resistance in every patient.

The individual values are important as well. A patient with elevated triglycerides, low HDL, increasing waist circumference and rising glucose presents a much more convincing metabolic pattern than a ratio interpreted without the rest of the lipid panel.

The Triglyceride-Glucose Index

The triglyceride-glucose index, usually shortened to the TyG index, combines fasting triglycerides and fasting glucose into another surrogate estimate of insulin resistance.

Interest in TyG has grown because both measurements are inexpensive and routinely obtained in clinical care. Studies have associated higher TyG values with insulin resistance, metabolic syndrome, type 2 diabetes and cardiovascular risk.

The limitation is familiar: there is no agreed universal threshold.

Different studies use different formulas, populations, reference methods and cutoffs. The TyG index may be useful for identifying an adverse metabolic pattern or following research populations, but it should not be treated as a stand-alone diagnostic test for insulin resistance.

Other Blood Tests Add Context Without Diagnosing Insulin Resistance

Insulin resistance frequently appears alongside other metabolic abnormalities, which is why a broader laboratory panel can be useful.

Triglycerides and HDL have already been discussed. Liver enzymes can provide clues when metabolic dysfunction-associated steatotic liver disease is present, although normal liver enzymes do not rule out fatty liver.

ApoB helps quantify the number of atherogenic lipoprotein particles and is valuable for cardiovascular risk assessment. It does not diagnose insulin resistance.

High-sensitivity C-reactive protein may identify inflammatory burden, but inflammation has many causes and hsCRP is not an insulin-resistance test.

Uric acid can rise in metabolic dysfunction and is associated with cardiometabolic risk, but it should not be used as a surrogate diagnosis of insulin resistance.

These markers help describe the terrain around the glucose and insulin problem. They do not replace measurements of glucose metabolism.

Visceral Fat Can Explain Laboratory Results the Scale Cannot

Laboratory testing is only part of metabolic assessment.

Visceral adipose tissue has a particularly strong relationship with insulin resistance and cardiometabolic disease. Two people with the same weight or BMI can carry very different amounts of visceral fat and have very different metabolic risk.

This is one reason body composition can be useful when laboratory results are borderline or when risk seems out of proportion to body weight.

Whole-body DEXA can estimate total fat, regional fat distribution, visceral adipose tissue and lean mass while also measuring bone density. It does not directly measure insulin sensitivity, but it can show whether the body-composition pattern associated with metabolic dysfunction is present.

SECA medical bioimpedance provides another way to follow changes in fat mass, lean mass and body water more frequently over time.

At HormoneSynergy®, body composition is interpreted alongside metabolic laboratory testing rather than as a substitute for it.

Learn more about DEXA Body Composition, Bone Density, and Visceral Fat and Body Composition and Longevity Medicine.

What About Continuous Glucose Monitoring?

Continuous glucose monitors have made post-meal glucose patterns visible in a way that was previously difficult outside a research or diabetes setting.

They can be useful for understanding how glucose behaves throughout the day and how meals, exercise, sleep and medications affect an individual response.

CGM should not be confused with a diagnostic test for insulin resistance.

The American Diabetes Association's 2026 standards state that there is currently insufficient evidence to use continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.

A normal-looking CGM trace also does not prove normal insulin sensitivity. A person may maintain glucose within a relatively narrow range partly because the pancreas is secreting substantial amounts of insulin.

CGM can add information. It does not replace fasting glucose, A1C, an OGTT or clinical judgment.

Which Tests Are Most Useful?

When Should Metabolic Testing Be Considered?

Current ADA guidance recommends screening for prediabetes and type 2 diabetes beginning at age 35 for adults who do not otherwise meet earlier screening criteria.

Testing should be considered earlier in adults with overweight or obesity who also have risk factors such as a first-degree relative with diabetes, cardiovascular disease, hypertension, low HDL or elevated triglycerides, polycystic ovary syndrome, physical inactivity or clinical conditions associated with insulin resistance.

People with prediabetes should generally be tested at least annually.

Clinical reasons to look more closely at insulin resistance can also include increasing abdominal fat, metabolic dysfunction-associated steatotic liver disease, acanthosis nigricans, substantial weight gain or a strong family history of type 2 diabetes.

Persistent fatigue by itself is too nonspecific to diagnose insulin resistance and should not be treated as though it is a metabolic biomarker.

How We Think About Insulin Resistance at HormoneSynergy®

There is a tendency in preventive medicine to search for one number that reveals a hidden diagnosis. Insulin resistance does not cooperate particularly well with that approach.

Fasting insulin can be useful. HOMA-IR can be useful. Triglycerides, HDL, glucose and A1C all contribute information. In selected patients, an oral glucose tolerance test can expose impaired glucose handling that was not apparent in fasting measurements.

None of these numbers tells us where visceral fat is accumulating, whether muscle is being preserved, how physically active the person is, whether sleep apnea is present or whether cardiovascular risk is already increasing.

At HormoneSynergy®, metabolic assessment may therefore combine laboratory testing with DEXA or SECA body composition, blood pressure, cardiovascular risk markers, clinical history and the patient's actual trajectory over time.

The purpose is not to diagnose insulin resistance earlier simply so that another label can be added to the chart. It is to identify a pattern early enough that something useful can still be done about it.

For a broader discussion, read Insulin Resistance: Early Signs, Causes, and What It Means for Longevity and Metabolic Health and Longevity Medicine.

Frequently Asked Questions

What blood test is best for insulin resistance?

There is no single routine blood test that directly diagnoses insulin resistance. Fasting insulin and HOMA-IR can provide useful estimates, while fasting glucose, A1C and a 2-hour oral glucose tolerance test evaluate abnormalities in glucose regulation. Results are most useful when interpreted together with body composition and cardiometabolic risk factors.

Can insulin resistance exist with normal fasting glucose?

Yes. The pancreas can sometimes compensate for reduced insulin sensitivity by secreting more insulin, allowing fasting glucose to remain below the prediabetes range for a period of time.

What is an optimal fasting insulin level?

There is no universally accepted fasting-insulin value that defines optimal insulin sensitivity. Values sometimes promoted online, such as less than 5 µIU/mL, are not universal diagnostic standards. Interpretation depends on the laboratory, fasting glucose, metabolic context and other risk factors.

What is a normal HOMA-IR?

There is no single HOMA-IR cutoff that applies to every population. Published thresholds vary according to age, sex, ethnicity, study population and insulin assay. HOMA-IR is best treated as an estimate rather than a stand-alone diagnosis.

Is HOMA-IR better than A1C?

They answer different questions. HOMA-IR estimates insulin resistance from fasting glucose and insulin, while A1C estimates longer-term glucose exposure. Neither replaces the other.

Can an oral glucose tolerance test detect problems missed by A1C?

Yes. The ADA notes that the 2-hour glucose measurement during a 75-gram oral glucose tolerance test identifies more people with prediabetes and diabetes than fasting glucose or A1C thresholds alone.

Does the triglyceride-to-HDL ratio diagnose insulin resistance?

No. A higher TG/HDL ratio is associated with insulin resistance and metabolic syndrome, but proposed cutoffs vary by population and the ratio should be treated as a surrogate marker rather than a diagnosis.

What is the TyG index?

The triglyceride-glucose index combines fasting triglycerides and glucose into a surrogate marker associated with insulin resistance and cardiometabolic risk. Research is promising, but there is no universally accepted clinical cutoff.

Can CGM diagnose insulin resistance?

No. Continuous glucose monitoring can show glucose patterns but does not measure insulin sensitivity. Current ADA guidance does not recommend CGM for screening or diagnosing prediabetes or diabetes.

Does visceral fat cause insulin resistance?

Higher visceral adiposity is strongly associated with insulin resistance and cardiometabolic disease. The relationship is biologically complex, but visceral fat is an important part of metabolic risk assessment and can be present even in people whose BMI does not appear markedly elevated.

Related HormoneSynergy® Reading

• HOMA-IR and Insulin Resistance: How to Interpret the Number
• Insulin Resistance: Early Signs, Causes, and What It Means for Longevity
• The Metabolic Health Crisis Is Not a Supplement Deficiency
• Metabolic Health and Longevity Medicine
• Body Composition and Longevity Medicine
• DEXA Body Composition, Bone Density, and Visceral Fat

Selected Research and Clinical Guidance

• American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
• Biomarkers of insulin sensitivity/resistance. Review of HOMA-IR, fasting insulin, TyG and other surrogate markers, including limitations of insulin assay standardization.
• The Triglyceride/HDL Ratio as a Surrogate Biomarker for Insulin Resistance. 2024.
• Triglyceride-glucose index and health outcomes: an umbrella review of systematic reviews and meta-analyses. 2024.
• Defining Insulin Resistance From Hyperinsulinemic-Euglycemic Clamps. Diabetes Care.
• Centers for Disease Control and Prevention. National Diabetes Statistics Report. Updated 2026.

Important Notice: This article is educational and is not a substitute for individualized medical care. Laboratory values should be interpreted in the context of medical history, medications, body composition, symptoms and other clinical findings.